KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsBuildingsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Biogen (BIIB) Assets (2016 - 2025)

Biogen has reported Assets over the past 17 years, most recently at $29.4 billion for Q4 2025.

  • Quarterly results put Assets at $29.4 billion for Q4 2025, up 4.96% from a year ago — trailing twelve months through Dec 2025 was $29.4 billion (up 4.96% YoY), and the annual figure for FY2025 was $29.4 billion, up 4.96%.
  • Assets for Q4 2025 was $29.4 billion at Biogen, up from $29.2 billion in the prior quarter.
  • Over the last five years, Assets for BIIB hit a ceiling of $29.4 billion in Q4 2025 and a floor of $23.6 billion in Q1 2022.
  • Median Assets over the past 5 years was $25.9 billion (2023), compared with a mean of $26.2 billion.
  • Biggest five-year swings in Assets: decreased 8.67% in 2021 and later grew 13.43% in 2023.
  • Biogen's Assets stood at $23.9 billion in 2021, then grew by 2.83% to $24.6 billion in 2022, then grew by 9.33% to $26.8 billion in 2023, then grew by 4.49% to $28.0 billion in 2024, then grew by 4.96% to $29.4 billion in 2025.
  • The last three reported values for Assets were $29.4 billion (Q4 2025), $29.2 billion (Q3 2025), and $28.3 billion (Q2 2025) per Business Quant data.